Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jie-Qin Wang

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Scientific Reports|August 1, 2025
Multihop cost awareness task migration with networking load balance technology for vehicular edge computingShih-Yang Lin, Jie-Qin Wang, Shi-Ming Peng, et al.
International Journal of Biological Sciences|March 17, 2020
Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic CholangiocarcinomaHua-Dong Chen, Chen-Song Huang, Qiong-Cong Xu, et al.
Advanced Healthcare Materials|December 27, 2025
Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH-Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX ModelChen-Song Huang, Chunlei Dai, Qi Liu, et al.
Cancer Science|August 7, 2019
EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552Xiao-Xu Zhu, Jian-Hui Li, Jian-Peng Cai, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2020
Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal AdenocarcinomaChen-Song Huang, Xinru You, Chunlei Dai, et al.
Nanoscale|July 31, 2020
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapyJie-Qin Wang, Li-Ying Wang, Shi-Jin Li, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 29, 2019
MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathwayJian-Hui Li, Xiao-Xu Zhu, Fu-Xi Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 17, 2022
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancerYin-Hao Shi, Qiong-Cong Xu, Ying-Qin Zhu, et al.
Oncogene|June 24, 2024
N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistanceMing-Jian Ma, Yin-Hao Shi, Zhi-De Liu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 3, 2024
Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal AdenocarcinomaYing-Qin Zhu, Yue Huang, Yin-Hao Shi, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Scientific Reports|August 1, 2025
Multihop cost awareness task migration with networking load balance technology for vehicular edge computingShih-Yang Lin, Jie-Qin Wang, Shi-Ming Peng, et al.
International Journal of Biological Sciences|March 17, 2020
Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic CholangiocarcinomaHua-Dong Chen, Chen-Song Huang, Qiong-Cong Xu, et al.
Advanced Healthcare Materials|December 27, 2025
Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH-Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma PDX ModelChen-Song Huang, Chunlei Dai, Qi Liu, et al.
Cancer Science|August 7, 2019
EYA4 inhibits hepatocellular carcinoma by repressing MYCBP by dephosphorylating β-catenin at Ser552Xiao-Xu Zhu, Jian-Hui Li, Jian-Peng Cai, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 11, 2020
Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal AdenocarcinomaChen-Song Huang, Xinru You, Chunlei Dai, et al.
Nanoscale|July 31, 2020
Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapyJie-Qin Wang, Li-Ying Wang, Shi-Jin Li, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 29, 2019
MFAP5 facilitates the aggressiveness of intrahepatic Cholangiocarcinoma by activating the Notch1 signaling pathwayJian-Hui Li, Xiao-Xu Zhu, Fu-Xi Li, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 17, 2022
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancerYin-Hao Shi, Qiong-Cong Xu, Ying-Qin Zhu, et al.
Oncogene|June 24, 2024
N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistanceMing-Jian Ma, Yin-Hao Shi, Zhi-De Liu, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 3, 2024
Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal AdenocarcinomaYing-Qin Zhu, Yue Huang, Yin-Hao Shi, et al.
Pageof 2